Long-term and low-dose treatment with Cabergoline induces macroprolactinoma shrinkage

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 11, 1997, Pages 3574-3579

  Colao, Annamaria ^a   Di Sarno, Antonella ^a   Landi, Maria Luisa ^a   Cirillo, Sossio ^a   Sarnacchiaro, Francesca ^a   Facciolli, Giuseppina ^a   Pivonello, Rosario ^a   Cataldi, Mauro ^a   Merola, Bartolomeo ^a   Annunziato, Lucio ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; PROLACTIN;

ADOLESCENT; ADULT; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; LONG TERM CARE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

EID: 9844235352     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.82.11.4368     Document Type: Article

References (19)

1. Cunnah D, Besser M. 1991 Management of prolactinomas. Clin Endocrinol (Oxf). 34:231-235.
2. Vance M, Evans W, Thorner M. 1984 Bromocriptine. Ann Intern Med. 100:78-91.
3. Liuzzi A, Dallabonzana D, Oppizzi G, et al. 1985 Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med. 313:656-659.
4. Bevan JS, Webster J, Burke CW, Scanlon MF. 1992 Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 13:221-235.
5. Grossman A, Bouloux PMG, Loneragan R, Rees LH, Wass JAH, Besser GM. 1985 Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinemia. Clin Endocrinol (Oxf). 22:611-616.
6. Schettini G, Lombardi G, Merola B, et al. 1990 Rapid and long-lasting suppression on prolactin secretion and shrinkage of prolactinomas with improved tolerability after injection of long-action repeatable form of bromocriptine (Parlodel LAR). Clin Endocrinol (Oxf). 33:161-169.
7. Khalfallah Y, Clustrat B, Grochowicki M, et al. 1990 Effects of a new prolactin inhibitor, CV 205-502, in the treatment of human macroprolactinomas. J Clin Endocrinol Metab. 71:354-359.
8. Colao A, Merola B, Sarnacchiaro F, et al. 1995 Comparison among different dopamine-agonists of new formulation in the clinical management of macro-prolactinoma. Horm Res. 44:222-228.
9. Ferrari C, Barbieri C, Caldara R, et al. 1986 Long-lasting prolactin lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab. 63:941-945.
10. Ciccarelli E, Giusti M, Miola A, et al. 1989 Effectiveness and tolerability of long-term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab. 69:725-728.
11. Webster J, Piscitelli G, Polli A, et al. 1992 Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinemia: a placebo controlled, double blind, multicentric study. Clin Endocrinol (Oxf). 37:534-541.
12. Webster J, Piscitelli G, Polli A, et al. 1994 A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med. 331:904-909.
13. Colao A, Di Sarno A, Sarnacchiaro F, et al. 1997 Prolactinomas resistant to other dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 83:876-883.
14. Biller BMK, Molitch ME, Vance ML, et al. 1996 Treatment of prolactin-secreting macroadenoma with once-a week dopamine agonist cabergoline. J Clin Endocrinol Metab. 81:2338-2343.
15. Lundin P, Pedersen F. 1992 Volume of pituitary macroadenomas: assessment by MRI. J Comput Assist Tomogr. 16:519-528.
16. Esiri MM, Bevan JS, Burke CW, Adams CBT. 1986 Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and non-functioning macroadenomas of the pituitary gland. J Clin Endocrinol Metab. 63:383-388.
17. Faglia G. 1991 Should dopamine agonists treatment for prolactinomas be life-long? Clin Endocrinol (Oxf). 34:173-174.
18. Strolin-Benedetti M, Dostert P, Barone D, Efthymiopoulos C, Peretti G, Roncucci R. 1990 In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine. Eur J Pharmacol. 187:399-408.
19. Persiani S, Sassolas G, Piscitelli G, et al. 1994 Pharmacodynamics and relative bioavailability of cabergoline tablets vs. solution in healthy volunteers. J Pharm Sci. 83:1421-1424.